文献速递银屑病与炎症性皮肤病

银屑病治疗对循环瘦素、脂联素和抵抗素水平的影响:系统综述与Meta分析

Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis.
PubMed 文献 · Br J Dermatol · 2018-05-16

该系统综述与Meta分析检索三个数据库,纳入评估银屑病患者在任何局部或系统治疗前后瘦素、脂联素或抵抗素浓度的研究。治疗后瘦素和脂联素浓度与治疗前相似,抵抗素浓度显著低于治疗前,但研究间存在显著异质性。

要点

  • 银屑病治疗后循环瘦素浓度与治疗前相似(SMD 0.06,95%CI -0.09至0.20),研究间无异质性。
  • 银屑病治疗后循环脂联素浓度与治疗前相似(SMD -0.14,95%CI -0.34至0.05),研究间有显著异质性。
  • 银屑病治疗后循环抵抗素浓度显著低于治疗前(SMD 0.50,95%CI 0.20至0.79),作者认为该发现预期具有临床重要性。

核心结论

  • 没有证据表明银屑病治疗改变瘦素和脂联素浓度,但治疗干预降低抵抗素浓度,作者认为该发现预期具有临床重要性。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Central和Embase三个数据库,纳入评估银屑病患者在任何局部或系统治疗前后瘦素、脂联素或抵抗素浓度的研究。

主要发现

  • 治疗后血瘦素浓度与治疗前相似(SMD 0.06,95%CI -0.09至0.20),研究间无异质性(I²=0%,P=0.88)。
  • 治疗后血脂联素浓度与治疗前相似(SMD -0.14,95%CI -0.34至0.05),研究间有显著异质性(I²=36.8%,P=0.032)。
  • 治疗后血抵抗素浓度显著低于治疗前(SMD 0.50,95%CI 0.20至0.79),研究间有显著异质性(I²=61.4%,P<0.001)。

局限性

  • 脂联素分析的研究间存在显著异质性(I²=36.8%,P=0.032)。
  • 抵抗素分析的研究间存在显著异质性(I²=61.4%,P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic syndrome, a risk factor of cardiovascular disease, is more common in patients with psoriasis than in the general population. Circulating adipokine concentrations are altered in patients with psoriasis and are suggested to represent the pathophysiological link between psoriatic lesions and metabolic alterations. OBJECTIVES: To perform a systematic review of the literature for studies that investigated possible differences in circulating levels of leptin, adiponectin or resistin in patients with psoriasis before and after any treatment intervention, and to meta-analyse the best evidence available. METHODS: A search was conducted in three databases (PubMed, Central and Embase). Eligible for the review were studies that assessed leptin, adiponectin or resistin concentrations in patients with psoriasis before and after any topical or systemic treatment. RESULTS: After treatment, blood concentrations of leptin were similar to those before treatment [standardized mean difference (SMD) 0·06, 95% confidence interval (CI) -0·09 to 0·20], with no heterogeneity among studies (I2 = 0%, P = 0·88). After treatment, blood concentrations of adiponectin were similar to those before treatment (SMD -0·14, 95% CI -0·34 to 0·05), with significant heterogeneity among studies (I2 = 36·8%, P = 0·032). After treatment, blood concentrations of resistin were significantly lower than those before treatment (SMD 0·50, 95% CI 0·20-0·79), with significant heterogeneity among studies (I2 = 61·4%, P < 0·001). CONCLUSIONS: There is no evidence that treatment for psoriasis modifies leptin and adiponectin concentrations. However, treatment intervention reduces resistin concentrations, a finding that is expected to be of clinical importance.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kyriakou A, Patsatsi A, Sotiriadis D, et al. Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol. 2018. PMID: 29432655. doi:10.1111/bjd.16437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。